Clinical Problem
250 million people worldwide suffer from osteoporosis, a bone disease characterized by a decrease in bone mass and a deterioration of the bone microarchitecture resulting in an increased fracture risk.
The presence of prevalent fractures doubles the risk for sustaining another fractures within the next 12 months.
For those patients at very high, imminent fracture risk, bone specialists are lacking a fast-acting treatment to locally strengthen fragile bones to prevent devastating fractures.
At flowbone, we address this treatment gap.
Our Solution
flowbone provides a new generation of injectable, "bone-seeding" gel for a quick and subtle, local strengthening of fragile bones.
-
Unique Mode of Action
Once in place, the gel initiates the deposition of the body's own minerals and rapidly turns into strong, viable bone
-
Compliance with Bone Biology
No foreign material, no interference with bone vascularization and biomechanics
-
Minimal Invasiveness
The gel is injected with a cannula into bone regions at hight risk of fracture
flowbone Ltd. was created in July 2020 as spin-off of the at the Laboratory of Biomechanical Orthopedics at the Swiss Federal Institute of Technology Lausanne (EPFL). It is headquartered at EPFL Innovation Park (canton Vaud, Switzerland).
All our products are still under development and not available on the market.
At flowbone, we aim for a world where the elderly can enjoy a high level of independence and quality of life, free from the devastating impact of fragility fractures.
About Us
Ulrike Kettenberger
CTO & Co-Founder
Régis Gauderon
CEO & Co-Founder
Dominique Pioletti
Advisor & Co-Founder
Arne Vogel
Market Access Manager
Anne-Céline Kohler
Product Development Engineer
Paul Note
Chairman of the Board
Join our team
We do not have any open positions at the moment.
Our Supporters
